5-氯-2-肼基苯甲酸盐酸盐 | 69196-08-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氯-2-肼基苯甲酸盐酸盐
• 英文名称: 5-chloro-2-hydrazinylbenzoic acid hydrochloride
• 英文别名: 5-Chloro-2-hydrazinobenzoic acid hydrochloride；5-chloro-2-hydrazinylbenzoic acid;hydrochloride
• CAS: 69196-08-3
• 化学式: C₇H₇ClN₂O₂*ClH
• 分子量: 223.059
• InChiKey: XCRANKQWSKKZLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.75
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氯-2-肼基苯甲酸盐酸盐 在 吡啶 、 盐酸 作用下， 反应 8.0h， 生成 5-氯-3-氧代-2H-吲唑-1-羧酸乙酯
  参考文献：
  名称：

  Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogs

  摘要：

  The apparent benefit of limiting serum cholesterol and triglyceride levels either by dietary restriction or drug therapy has prompted work in our laboratories toward development of a suitable antihyperlipidemic agent. We have demonstrated the antihyperlipidemic activity of a series of phthalimide derivatives in rodents to be significantly greater than that of clofibrate at a dose of 20 mg/(kg day), intraperitoneally. Here we report the synthesis and biological evaluation of a series of indazolone derivatives, which are heterocycles that are structurally related to the phthalimides . In general, structure-activity relationships within the phthalimide series may be extended to the indazolones . While indazolone itself is only moderately active, N1-carbethoxy substitution produced a more active compound. Substitution of the N2 position with an n-butyl group afforded the most active compound, as also seen in the phthalimide series. Aromatic substitution with electron-releasing and -withdrawing groups lessened the antihyperlipidemic activity.

  DOI：

  10.1021/jm00372a011
• 作为产物：
  描述：

  2-氨基-5-氯苯甲酸 在 盐酸 、 sodium sulfite 、 sodium nitrite 作用下， 生成 5-氯-2-肼基苯甲酸盐酸盐
  参考文献：
  名称：

  Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogs

  摘要：

  The apparent benefit of limiting serum cholesterol and triglyceride levels either by dietary restriction or drug therapy has prompted work in our laboratories toward development of a suitable antihyperlipidemic agent. We have demonstrated the antihyperlipidemic activity of a series of phthalimide derivatives in rodents to be significantly greater than that of clofibrate at a dose of 20 mg/(kg day), intraperitoneally. Here we report the synthesis and biological evaluation of a series of indazolone derivatives, which are heterocycles that are structurally related to the phthalimides . In general, structure-activity relationships within the phthalimide series may be extended to the indazolones . While indazolone itself is only moderately active, N1-carbethoxy substitution produced a more active compound. Substitution of the N2 position with an n-butyl group afforded the most active compound, as also seen in the phthalimide series. Aromatic substitution with electron-releasing and -withdrawing groups lessened the antihyperlipidemic activity.

  DOI：

  10.1021/jm00372a011

文献信息

• [EN] SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE TRIAZOLE SUBSTITUÉS ET UTILISATIONS ASSOCIÉES
  申请人：BAYER AG

  公开号：WO2019081307A1

  公开（公告）日：2019-05-02

  Substituted triazole derivatives and uses thereof The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

  取代的三唑衍生物及其用途 本发明涉及新型的取代的1,2,4-三唑衍生物，制备这类化合物的方法，含有这类化合物的药物组合物，以及利用这类化合物或组合物治疗和/或预防疾病的用途，特别是用于治疗和/或预防肾脏和心血管疾病。
• Therapeutic preparations containing indazole derivatives
  申请人：ICI Pharma

  公开号：US05173496A1

  公开（公告）日：1992-12-22

  The invention concerns pharmaceutical compositions containing a 1,2-dihydro-3H-indazol-3-one derivative of the formula I ##STR1## wherein Ra is hydrogen, halogeno, nitro, hydroxy, (2-6C)alkanoyloxy, (1-6C)alkyl, (1-6C)alkoxy, fluoro-(1-4C)alkyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-4C)alkyl]amino, (2-6C)alkanoylamino or hydroxy-(1-6C)alkyl; Rb is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; and Y is a group of the formula --A.sup.1 --X--A.sup.2 --Q in which A.sup.1 is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene, or A.sup.1 is phenylene; X is oxy, thio, sulphinyl, sulphonyl, imino, (1-6C)alkylimino, (1-6C)alkanoylimino, iminocarbonyl or phenylene, or X is a direct link to A.sup.2 ; A.sup.2 is (1-6C)alkylene, (3-6C)alkenylene or (3-6C)alkynylene or A.sup.2 is cyclo(3-6C)alkylene or is a direct link to Q, or the group --A.sup.1 --X--A.sup.2 -- is a direct link to Q; or Y is (2-10)alkyl, (3-10C)alkenyl or (3-6C)alkynyl; and Q is aryl or heteroaryl. The invention also provides novel 1,2-dihydro-3H-indazol-3-ones, processes for their production and the use of 1,2-dihydro-3H-indazol-3-ones for the manufacture of medicaments for the treatment of various allergic and inflammatory diseases.

  本发明涉及含有1,2-二氢-3H-吲唑-3-酮衍生物的制药组合物，其化学式为I ##STR1## 其中Ra为氢，卤素，硝基，羟基，(2-6C)脂肪酰氧基，(1-6C)烷基，(1-6C)烷氧基，氟代-(1-4C)烷基，(2-6C)脂肪酰基，氨基，(1-6C)烷基氨基，二-[(1-4C)烷基]氨基，(2-6C)脂肪酰氨基或羟基-(1-6C)烷基；Rb为氢，卤素，(1-6C)烷基或(1-6C)烷氧基；Y为公式--A.sup.1 --X--A.sup.2 --Q的基团，其中A.sup.1为(1-6C)烷基，(3-6C)烯基，(3-6C)炔基或环(3-6C)烷基，或A.sup.1为苯基；X为氧，硫，亚磺酰基，磺酰基，亚胺，(1-6C)烷基亚胺，(1-6C)脂肪酰基亚胺，亚氨基甲酰基或苯基，或X为与A.sup.2的直接连接；A.sup.2为(1-6C)烷基，(3-6C)烯基或(3-6C)炔基，或A.sup.2为环(3-6C)烷基或与Q的直接连接，或基团--A.sup.1 --X--A.sup.2 --为与Q的直接连接；或Y为(2-10)烷基，(3-10C)烯基或(3-6C)炔基；Q为芳基或杂芳基。本发明还提供了新的1,2-二氢-3H-吲唑-3-酮，其制备过程以及用于制造治疗各种过敏和炎症疾病的药物的1,2-二氢-3H-吲唑-3-酮的用途。
• Therapeutic preparations
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0284174A1

  公开（公告）日：1988-09-28

  The invention concerns pharmaceutical compositions containing a 1,2-dihydro-3H-indazol-3-one derivative of the formula I wherein Ra is hydrogen, halogeno, nitro, hydroxy, (2-6C)alkanoyloxy, (1-6C)alkyl, (1-6C)alkoxy, fluoro-(1-4C)alkyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-4C)alkyl]amino, (2-6C)alkanoylamino or hydroxy-­(1-6C)alkyl; Rb is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; and Y is a group of the formula -A¹-X-A²-Q in which A¹ is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene, or A¹ is phenylene; X is oxy, thio, sulphinyl, sulphonyl, imino, (1-­6C)alkylimino, (1-6C)alkanoylimino, iminocarbonyl or phenylene, or X is a direct link to A²; A² is (1-6C)alkylene, (3-6C)alkenylene or (3-­6C)alkynylene or A² is cyclo(3-6C)alkylene or is a direct link to Q, or the group A¹-X-A² is a direct link to Q; or Y is (2-10)alkyl, (3-­10C)alkenyl or (3-6C)alkynyl; and Q is aryl or heteroaryl. The invention also provides novel 1,2-dihydro-3H-indazol-3-­ones, processes for their production and the use of 1,2-dihydro-3H-­indazol-3-one for the manufacture of medicaments for the treatment of various allergic and inflammatory diseases.

  本发明涉及含有式 I 的 1,2-二氢-3H-吲唑-3-酮衍生物的药物组合物 其中Ra是氢、卤素、硝基、羟基、(2-6C)烷酰氧基、(1-6C)烷基、(1-6C)烷氧基、氟-(1-4C)烷基、(2-6C)烷酰基、氨基、(1-6C)烷基氨基、二[(1-4C)烷基]氨基、(2-6C)烷酰氨基或羟基-(1-6C)烷基；Rb 是氢、卤素、(1-6C)烷基或 (1-6C)烷氧基；以及 Y 是式 -A¹-X-A²-Q 的基团，其中 A¹ 是 (1-6C)亚烷基、(3-6C)烯基、(3-6C)炔基或环(3-6C)亚烷基，或 A¹ 是亚苯基；X 是氧基、硫代、亚砜基、磺酰基、亚氨基、(1-6C)烷基亚氨基、(1-6C)烷酰亚氨基、亚氨基羰基或亚苯基，或 X 是与 A² 的直接连接；A²是(1-6C)亚烷基、(3-6C)亚烯基或(3-6C)亚炔基，或A²是环(3-6C)亚烷基，或与Q直接相连，或基团A¹-X-A²与Q直接相连；或Y是(2-10)烷基、(3-10C)亚烯基或(3-6C)亚炔基；且Q是芳基或杂芳基。 本发明还提供了新型 1,2-二氢-3H-吲唑-3-酮、其生产工艺以及 1,2-二氢-3H-吲唑-3-酮用于制造治疗各种过敏性和炎症性疾病的药物。
• FUSED POLYCYCLIC HETEROCYCLE DERIVATIVES
  申请人：Eisai Co., Ltd.

  公开号：EP0831094A1

  公开（公告）日：1998-03-25

  Novel fused polycyclic heterocycle derivatives having excellent antitumor effects and a process for producing the same. A compound represented by the following general formula (I) or pharmacologically acceptable salts thereof: wherein the ring A represents an optionally substituted monocyclic aromatic ring or a dicyclic fused ring in which at least one of the rings is an aromatic ring; the ring B represents pyrrole, 4H-1,4-oxazine, 4H-1,4-thiazine or 4(1H)-pyridone; the ring C represents an optionally substituted, monocyclic or dicyclic fused aromatic ring; and Y represents a group represented by the formula -e-f (wherein e represents a lower alkylene; and f represents amidino, guanidino or amino optionally substituted by optionally hydroxylated or optionally lower-alkylaminated lower alkyl;    provided that the cases where the rings A and B are both optionally substituted monocyclic aromatic rings are excluded. Which has an excellent antitumor activity.

  具有优异抗肿瘤效果的新型融合多环杂环衍生物及其生产工艺。 由以下通式(I)代表的化合物或其药理学上可接受的盐： 其中，环 A 代表任选取代的单环芳香环或二环融合环，其中至少有一个环是芳香环； 环 B 代表吡咯、4H-1,4-恶嗪、4H-1,4-噻嗪或 4(1H)-吡啶酮；环 C 代表任选取代的单环或双环融合芳环；以及 Y 代表由式-e-f 所代表的基团（其中 e 代表低级亚烷基；f 代表脒基、胍基或任选被羟基化或任选被低级烷基酰胺化的低级烷基取代的氨基）； 但不包括环 A 和环 B 均为任选取代的单环芳香环的情况。 具有极佳的抗肿瘤活性。
• Substituted triazole derivatives and uses thereof
  申请人：BAYER AKTIENGESELLSCHAFT

  公开号：US11173151B2

  公开（公告）日：2021-11-16

  The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

  本发明涉及新型取代的 1,2,4-三唑衍生物、制备此类化合物的工艺、含有此类化合物的药物组合物，以及使用此类化合物或组合物治疗和/或预防疾病，特别是治疗和/或预防肾病和心血管疾病。